Unified Patent Court (UPC) analytics are now available. Check here

EP3461474

GLAXOSMITHKLINE
Application Number
EP18201769A
Filing Date
Aug 31, 2011
Status
Revoked
May 27, 2022
Grant Date
Nov 11, 2020
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Biblio Summary

The patent EP3461474B1 was granted on Nov 11, 2020 by Glaxosmithkline The patent is currently Revoked.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKAug 11, 2021ADMISSIBLE
HGFAug 9, 2021ADMISSIBLE
TEVA UKJul 13, 2021ADMISSIBLE
SANDOZJun 25, 2021ADMISSIBLE

Patent citations in opposition refer to prior patents or publications that may challenge the validity of a contested patent. These references help assess whether the invention is truly novel or overlaps with existing intellectual property.

Citation PhasePatent NumberPatent LinkCited Text
OppositionEP2611422B1
N/A
OppositionWO2004105727
N/A
OppositionUS7101866
N/A
OppositionWO2008040841
N/A
OppositionWO2008135570
N/A
OppositionWO2009013243
N/A
OppositionUS2010189780
N/A
OppositionWO2010135340
N/A
OppositionUS2011036733
N/A
OppositionWO2007109606
N/A
OppositionWO2009013244
N/A
OppositionEP2954888
N/A
OppositionWO0198174
N/A
OppositionEP2611423
N/A
OppositionUS2005039743
N/A
OppositionWO2005044186
N/A

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.